In one paragraphArticle in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
Brandon M HuffmanBrandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-0768-3145 Adham JurdiBrandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-2985-3053 Alexey AleshinBrandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-0425-0301 Minetta C LiuBrandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-8206-5232 Samuel J KlempnerBrandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
What OpenQuestion holds
Textmetadata
Read underepoch 390